Application of bacteroides fragilis and zwitterionic capsular polysaccharide thereof in preparation of medicine for preventing and treating tumors of genitourinary system

A technology of Bacteroides fragilis and capsular polysaccharide, applied in the field of biomedicine, can solve the problem of no urogenital system cancer prevention and/or treatment, and achieve the effect of enhancing body immunity

Active Publication Date: 2022-04-15
GUANGZHOU ZHIYI PHARMA INC
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] However, there is currently no documented use of Bacteroides fragilis and/or its zwi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacteroides fragilis and zwitterionic capsular polysaccharide thereof in preparation of medicine for preventing and treating tumors of genitourinary system
  • Application of bacteroides fragilis and zwitterionic capsular polysaccharide thereof in preparation of medicine for preventing and treating tumors of genitourinary system
  • Application of bacteroides fragilis and zwitterionic capsular polysaccharide thereof in preparation of medicine for preventing and treating tumors of genitourinary system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] The fermentation culture of embodiment 1 Bacteroides fragilis

[0070] Streak inoculation of Bacteroides fragilis ZY-312 strain on blood plate, anaerobic culture for 48h. Observe the colony morphological characteristics, staining characteristics, size, club shape and distribution, etc.

[0071] Colony characteristics: Bacteroides fragilis ZY-312, after being cultured on a blood plate for 48 hours, is slightly convex, translucent, white, smooth, non-hemolytic, and the diameter of the colony is between 1-3mm. See figure 1 .

[0072] Morphology under the microscope: Bacteroides fragilis ZY-312 was examined by Gram staining. It is a Gram-negative bacterium with a typical rod shape, blunt rounded ends and dense staining. The uncolored part in the middle of the bacteria is like a vacuole. figure 2 .

[0073] Select a single colony and inoculate it in plant-derived peptone liquid medium for fermentation and culture for 8 hours (at a temperature of 37°C) to obtain a bacteri...

Embodiment 2

[0075] Example 2 Preparation of Bacteroides fragilis capsular polysaccharide

[0076] The bacteria slime prepared in Example 1 was used to carry out the experiment.

[0077] (1) Take 50g of bacteria slime, add 300g of purified water to resuspend the bacteria, adjust its pH to 3.5 with 1mol / L hydrochloric acid solution, extract at 100°C for 1.5h, cool to room temperature, centrifuge at 12000g at room temperature for 10min, take the supernatant to obtain rough sugar solution;

[0078] (2) The crude sugar solution is concentrated by ultrafiltration through a 10KD ultrafiltration membrane to remove small molecular impurities until the conductivity is stable, and the reflux liquid is collected;

[0079] (3) Add an equal volume of 40mmol / L Tris-HCl (pH8.5) to the reflux liquid to convert the salt; .5, containing 0.2mol / L NaCl) gradient elution of 25 column volumes, segmented collection, 100mL / bottle (component), SEC-HPLC follow-up monitoring, combined 206nm absorption peak as a si...

Embodiment 3

[0081] Example 3 Drug efficacy test of Bacteroides fragilis and its zwitterionic capsular polysaccharides on mouse Renca renal carcinoma transplanted tumors

[0082] Renca cells in the logarithmic growth phase were adjusted to 1.5×10 cells with PBS 7 Cells / mL, inoculate 100 μL Renca cell suspension and 100 μL matrigel matrigel solution subcutaneously in the left flank of BALB / c mice with a syringe under sterile conditions. When the transplanted tumor grows to about 40-50mm 3 start administration, divided into control group (normal saline), positive drug group (sunitinib, Pfizer, 50mg / kg), Bacteroides fragilis ZY-312 low (10 6 CFU / only), medium (10 8 CFU / piece), high (10 10 CFU / only) dose group, Bacteroides fragilis ZY-312 inactivated bacteria (10 10 cell / mouse) group, Bacteroides fragilis ZY-312 capsular polysaccharide A (PSA, 500 μg / mouse) was continuously gavaged for 4 weeks. After the last administration, the mice were euthanized, and the transplanted tumors were excise...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Weight average molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of bacteroides fragilis and/or zwitterionic capsular polysaccharide thereof in preparation of a medicine for preventing and treating cancers of a urogenital system. The bacteroides fragilis, especially the bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 and the zwitter-ion capsular polysaccharide A of the bacteroides fragilis ZY-312 can regulate the levels of T cells and immune factors, enhance body immunity and effectively prevent and treat kidney cancer, bladder cancer, prostate cancer, bladder urinary tract epithelial cancer, ovarian cancer, breast cancer, cervical cancer and other urogenital system tumors.

Description

[0001] The microbial strains used in the implementation of the present invention have been preserved on April 2, 2015 at the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Management Committee (No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing). Taxonomic designation: Bacteroides fragilis ZY-312 (bacteroides fragilis ZY-312), deposit number CGMCC No. 10685. Bacteroides fragilis ZY-312 was isolated and obtained by the applicant unit of the present invention, and has been authorized for patent protection (patent number 201510459408.X). According to the provisions of the patent examination guidelines, the public can buy it from commercial channels or has authorized it without preservation, that is, No deposit certificate is required. technical field [0002] The invention relates to the field of biomedicine, in particular to the application of Bacteroides fragilis and / or its zwitterionic capsular polysaccharide in the prevention and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/715A61K35/741A61P13/00A61P35/00C08B37/00A23L33/125A23L33/135
CPCY02A50/30A23L33/125A23L33/135A61K31/715A61K35/741A61P13/00A61P35/00C08B37/00
Inventor 李平邝高波王从峰倪赛
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap